<産業資料/調査レポートの題名> 2022年6月15日

血漿分画の世界市場:製品別(アルブミン、免疫グロブリン、凝固第VIII因子)、用途別(神経学、血液学、免疫学、救命救急、その他)、エンドユーザー別(病院、研究所)


◆英文タイトル:Global Plasma Fractionation Market by Product (Albumin, Immunoglobulins, and Coagulation Factor VIII), Application (Neurology, Hematology, Immunology, Critical Care and Others), End User (Hospitals, and Research Laboratories): Global Opportunity Analysis and Industry Forecast, 2018–2028

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments

1.3.1. List Of Key Players Profiled In The Report

1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings Of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets

3.3. Porter’S Five Forces Analysis

3.3.1. Bargaining Power Of Buyers
3.3.2. Bargaining Power Of Suppliers
3.3.3. Thereat Of New Entrants
3.3.4. Threat Of Substitutes
3.3.5. Intensity Of Competitive Rivalry

3.4. Top Player Positioning, 2018
3.5. Market Dynamics

3.5.1. Drivers

3.5.1.1. Surge In Geriatric Population Across The Globe Coupled With Rise In Prevalence Of Rare Diseases
3.5.1.2. Rise In Use Of Immunoglobulins In Areas Of Medicine
3.5.1.3. Increase In Number Of Plasma Collection Centers Across The Globe

3.5.2. Restraint

3.5.2.1. High Cost Of Plasma Derived Products

3.5.3. Opportunity

3.5.3.1. High Growth Potential In Emerging Economies

3.5.4. Impact Analysis

Chapter 4: Plasma Fractionation Market, By Product

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Albumin

4.2.1. Key Market Trends And Growth Opportunities
4.2.2. Market Size And Forecast, By Country

4.3. Immunoglobulins

4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast, By Type

4.3.2.1. Subcutaneous Immunoglobulin

4.3.2.1.1. Market Size And Forecast

4.3.2.2. Intravenous Immunoglobulin

4.3.2.2.1. Market Size And Forecast

4.3.3. Market Size And Forecast, By Country

4.4. Coagulation Factor Viii

4.4.1. Key Market Trends And Growth Opportunities
4.4.2. Market Size And Forecast, By Country

Chapter 5: Plasma Fractionation Market, By Application

5.1. Overview

5.1.1. Market Size And Forecast

5.2. Neurology

5.2.1. Market Size And Forecast, By Region

5.3. Hematology

5.3.1. Market Size And Forecast, By Region

5.4. Immunology

5.4.1. Market Size And Forecast, By Region

5.5. Critical Care

5.5.1. Market Size And Forecast, By Region

5.6. Others

5.6.1. Market Size And Forecast, By Region

Chapter 6: Plasma Fractionation Market, By End User

6.1. Overview

6.1.1. Market Size And Forecast

6.2. Hospitals

6.2.1. Market Size And Forecast, By Region

6.3. Clinical Research Laboratories

6.3.1. Market Size And Forecast, By Region

Chapter 7: Plasma Fractionation Market, By Country

7.1. Overview

7.1.1. Market Size And Forecast

7.2. Russia

7.2.1. Key Market Trends And Growth Opportunities
7.2.2. Market Size And Forecast, By Product
7.2.3. Market Size And Forecast, By Application
7.2.4. Market Size And Forecast, By End User

7.3. Kazakhstan

7.3.1. Key Market Trends And Growth Opportunities
7.3.2. Market Size And Forecast, By Product
7.3.3. Market Size And Forecast, By Application
7.3.4. Market Size And Forecast, By End User

7.4. Indonesia

7.4.1. Key Market Trends And Growth Opportunities
7.4.2. Market Size And Forecast, By Product
7.4.3. Market Size And Forecast, By Application
7.4.4. Market Size And Forecast, By End User

7.5. China (Including Taiwan)

7.5.1. Key Market Trends And Growth Opportunities
7.5.2. Market Size And Forecast, By Product
7.5.3. Market Size And Forecast, By Application
7.5.4. Market Size And Forecast, By End User

7.6. India

7.6.1. Key Market Trends And Growth Opportunities
7.6.2. Market Size And Forecast, By Product
7.6.3. Market Size And Forecast, By Application
7.6.4. Market Size And Forecast, By End User

7.7. Saudi Arabia

7.7.1. Key Market Trends And Growth Opportunities
7.7.2. Market Size And Forecast, By Product
7.7.3. Market Size And Forecast, By Application
7.7.4. Market Size And Forecast, By End User

7.8. Egypt

7.8.1. Key Market Trends And Growth Opportunities
7.8.2. Market Size And Forecast, By Product
7.8.3. Market Size And Forecast, By Application
7.8.4. Market Size And Forecast, By End User

7.9. Vietnam

7.9.1. Key Market Trends And Growth Opportunities
7.9.2. Market Size And Forecast, By Product
7.9.3. Market Size And Forecast, By Application
7.9.4. Market Size And Forecast, By End User

7.10. Argentina

7.10.1. Key Market Trends And Growth Opportunities
7.10.2. Market Size And Forecast, By Product
7.10.3. Market Size And Forecast, By Application
7.10.4. Market Size And Forecast, By End User

7.11. Thailand

7.11.1. Key Market Trends And Growth Opportunities
7.11.2. Market Size And Forecast, By Product
7.11.3. Market Size And Forecast, By Application
7.11.4. Market Size And Forecast, By End User

7.12. Nigeria

7.12.1. Key Market Trends And Growth Opportunities
7.12.2. Market Size And Forecast, By Product
7.12.3. Market Size And Forecast, By Application
7.12.4. Market Size And Forecast, By End User

7.13. Rest Of The World

7.13.1. Key Market Trends And Growth Opportunities
7.13.2. Market Size And Forecast, By Product
7.13.3. Market Size And Forecast, By Application
7.13.4. Market Size And Forecast, By End User

Chapter 8: Company Profiles

8.1. Baxter International Inc.

8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance

8.2. Bio Products Laboratory

8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio

8.3. Biotest Ag

8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.3.6. Key Strategic Moves And Developments

8.4. Csl Ltd.

8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance

8.5. Grifols Sa

8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance

8.6. Kedrion Biopharma

8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance

8.7. Lfb S. A

8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance

8.8. Octapharma

8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio

8.9. Sanquin Blood Supply Foundation

8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance

8.10. Takeda Pharmaceutical Company Limited

8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
8.10.6. Key Strategic Moves And Developments


LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark